10-Q: NexGel Inc. Reports Strong Revenue Growth in Q3 2024 Driven by Branded Consumer Products

NexGel, Inc. saw a significant increase in revenue during the third quarter of 2024, primarily driven by its branded consumer products segment, including recent acquisitions.

Summary

• NexGel, Inc. reported a net revenue of $2.94 million for the three months ended September 30, 2024, a 140.8% increase compared to $1.22 million for the same period in 2023.
• The company's gross profit for the quarter was $1.28 million, a substantial increase from $0.34 million in the prior year, with a gross profit margin of 43.6% compared to 28.2% in 2023.
• Operating expenses totaled $2.07 million for the quarter, up from $0.96 million in 2023, primarily due to increased selling, general, and administrative costs.
• The net loss for the quarter was $0.75 million, compared to a net loss of $0.55 million in the same period last year.
• For the nine months ended September 30, 2024, the company's net revenue was $5.65 million, an 87.8% increase from $3.01 million in 2023.
• The net loss for the nine-month period was $2.64 million, compared to a net loss of $2.00 million in the same period last year.
• The company's cash balance was $1.06 million as of September 30, 2024, down from $2.70 million at the end of 2023.
• The company completed two equity offerings in 2024, raising approximately $2 million in net proceeds.
• The company acquired Silly George in May 2024 and Kenkoderm in December 2023, expanding its branded consumer product portfolio.

Sentiment

Score: 6

Explanation: The document shows strong revenue growth and strategic acquisitions, but the increasing net losses and decreasing cash balance temper the positive outlook. The company is in a growth phase with potential, but also faces significant financial challenges.

Positives

• The company experienced significant revenue growth, particularly in its branded consumer products segment.
• Gross profit margins improved substantially, indicating better profitability on sales.
• The company successfully completed two equity offerings, raising additional capital.
• The acquisitions of Silly George and Kenkoderm have expanded the company's product portfolio and market reach.

Negatives

• The company's net loss increased in both the three and nine-month periods compared to the previous year.
• Operating expenses, particularly selling, general, and administrative costs, increased significantly.
• The company's cash balance decreased substantially during the nine-month period.
• The company continues to incur losses and is dependent on its ability to manage and grow its current products to achieve profitability.

Risks

• The company's ability to continue as a going concern is dependent on its ability to manage and grow its current products and achieve profitable operations.
• The company may need to raise additional capital through debt or equity offerings to fund potential acquisitions and strategic initiatives.
• The company faces risks related to intense competition, loss of key customers or suppliers, and adverse government regulations.
• The company's financial statements do not include any adjustments relating to the recoverability and classification of recorded assets and liabilities that might be necessary should the company be unable to continue as a going concern.

Future Outlook

The company plans to continue growing its existing contract manufacturing business, develop its catalog of consumer products, and explore new product channels in cosmetics, athletic products, and medical devices. They also plan to develop proprietary medical devices and explore drug delivery programs. The company expects to continue incurring losses in the near term and may need to raise additional capital.

Management Comments

• Management is exploring new product channel sales in adjacent industries, such as cosmetics, athletic products, and proprietary medical devices.
• The Company has increased focus on sales and developing a sales pipeline for potential customers.
• We intend to maintain and attempt to grow our existing contract manufacturing business.
• We also plan to continue building and developing our catalogue of consumer products for sale to branding partners and to use our in-house capabilities to create and test market additional branded products.
• Furthermore, the Company plans to develop its own proprietary medical devices and explore drug delivery programs for its technology.

Industry Context

The company's expansion into branded consumer products, particularly with the acquisitions of Kenkoderm and Silly George, reflects a broader trend in the healthcare and beauty industries where companies are seeking to diversify their revenue streams and reach consumers directly. The company's focus on custom gels and proprietary manufacturing technologies positions it to capitalize on the growing demand for specialized and personalized products.

Comparison to Industry Standards

• NexGel's revenue growth of 140.8% in Q3 2024 is significantly higher than the average growth rate for companies in the medical device and consumer product sectors, which typically range from 5% to 20% annually.
• The company's gross profit margin of 43.6% is competitive with other companies in the consumer product space, but lower than some medical device companies that often have margins above 60%.
• The increase in operating expenses, particularly in marketing and advertising, is typical for companies that are expanding their branded consumer product lines.
• The company's net loss is not unusual for a growth-stage company that is investing heavily in expansion and acquisitions.
• Compared to companies like Johnson & Johnson or Procter & Gamble, NexGel is still a small player, but its growth trajectory is promising.
• The company's focus on hydrogel technology and custom manufacturing sets it apart from many competitors in the consumer product space.

Related Party Transactions

• Dr. Jerome Zeldis, a member of the Company board of directors, had an outstanding balance due of $25,000 for services as of December 31, 2023, which was repaid in August 2024.

Stakeholder Impact

• Shareholders may see potential for long-term growth, but also face the risk of continued losses and potential dilution from future capital raises.
• Employees may benefit from the company's growth and expansion, but also face the risk of potential financial instability.
• Customers may benefit from the company's expanded product offerings and improved manufacturing capabilities.
• Suppliers may see increased demand for their products as the company grows.
• Creditors may face increased risk due to the company's ongoing losses and need for additional capital.

Next Steps

• The company intends to maintain and grow its existing contract manufacturing business.
• The company plans to continue building and developing its catalog of consumer products.
• The company will use in-house capabilities to create and test market additional branded products.
• The company plans to develop its own proprietary medical devices and explore drug delivery programs.
• The company will continue to evaluate strategic initiatives and additional capital raises.

Key Dates

Keywords

hydrogels, contract manufacturing, branded consumer products, skincare, cosmetics, revenue growth, acquisitions, equity offering, financial results, Silly George, Kenkoderm